CoChat

Discovery of a novel potent peptide agonist to adiponectin receptor 1

Open access
Kim, Sunghwan, Lee, Younho, Kim, Jun Woo, Son, Young-Jin, Ma, Min Jung, Um, Jee-Hyun, Kim, Nam Doo, Min, Sang Hyun, Kim, Dong Il, Kim, Brian B. · 2018 · PLOS ONE
Cited by 44

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Abstract

Activation of adiponectin receptors (AdipoRs) by its natural ligand, adiponectin has been known to be involved in modulating critical metabolic processes such as glucose metabolism and fatty acid oxidation as demonstrated by a number of in vitro and in vivo studies over last two decades. These findings suggest that AdipoRs' agonists could be developed into a potential therapeutic agent for metabolic diseases, such as diabetes mellitus, especially for type II diabetes, a long-term metabolic disorder characterized by high blood sugar, insulin resistance, and relative lack of insulin. Because of limitations in production of biologically active adiponectin, adiponectin-mimetic AdipoRs' agonists have been suggested as alternative ways to expand the opportunity to develop anti-diabetic agents. Based on crystal structure of AdipoR1, we designed AdipoR1's peptide agonists using protein-peptide docking simulation and screened their receptor binding abilities and biological functions via surface plasmon resonance (SPR) and biological analysis. Three candidate peptides, BHD1028, BHD43, and BHD44 were selected and confirmed to activate AdipoR1-mediated signal pathways. In order to enhance the stability and solubility of peptide agonists, candidate peptides were PEGylated. PEGylated BHD1028 exhibited its biological activity at nano-molar concentration and could be a potential therapeutic agent for the treatment of diabetes. Also, SPR and virtual screening techniques utilized in this study may potentially be applied to other peptide-drug screening processes against membrane receptor proteins.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.pone.0199256

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 18

  1. Y Shi, 2014, The global implications of diabetes and cancer, Lancet, 383, 1947, 10.1016/S0140-6736(14)60886-2 · DOI · Paper page
  2. WL Holland, 2013, Cell Biology. Ronning after the adiponectin receptors, Science, 342, 1460, 10.1126/science.1249077 · DOI · Paper page
  3. T Yamauchi, 2002, Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase, Nat Med, 8, 1288, 10.1038/nm788 · DOI · Paper page
  4. AH Berg, 2001, The adipocyte-secreted protein Acrp30 enhances hepatic insulin action, Nat Med, 7, 947, 10.1038/90992 · DOI · Paper page
  5. J Fruebis, 2001, Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice, Proc Natl Acad Sci U S A, 98, 2005, 10.1073/pnas.98.4.2005 · doi:10.1073/pnas.98.4.2005 · Paper page
  6. T Yamauchi, 2001, The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity, Nat Med, 7, 941, 10.1038/90984 · DOI · Paper page
  7. F Mancia, 2004, Optimization of protein production in mammalian cells with a coexpressed fluorescent marker, Structure, 12, 1355, 10.1016/j.str.2004.06.012 · DOI
  8. UB Pajvani, 2003, Structure-function studies of the adipocyte-secreted hormone Acrp30/adiponectin. Implications fpr metabolic regulation and bioactivity, J Biol Chem, 278, 9073, 10.1074/jbc.M207198200 · DOI · Paper page
  9. L Otvos Jr., 2011, Design and development of a peptide-based adiponectin receptor agonist for cancer treatment, BMC Biotechnol, 11, 90, 10.1186/1472-6750-11-90 · DOI · Paper page
  10. H Tanabe, 2015, Crystal structures of the human adiponectin receptors, Nature, 520, 312, 10.1038/nature14301 · DOI · Paper page
  11. H Tanabe, 2015, Expression, purification, crystallization, and preliminary X-ray crystallographic studies of the human adiponectin receptors, AdipoR1 and AdipoR2, J Struct Funct Genomics, 16, 11, 10.1007/s10969-014-9192-z · DOI
  12. I Vasiliauskaite-Brooks, 2017, Structural insights into adiponectin receptors suggest ceramidase activity, Nature, 544, 120, 10.1038/nature21714 · DOI · Paper page
  13. DH Na, 2005, PEGylation of octreotide: II. Effect of N-terminal mono-PEGylation on biological activity and pharmacokinetics, Pharm Res, 22, 743, 10.1007/s11095-005-2590-y · DOI
  14. X Min, 2012, Crystal structure of a single-chain trimer of human adiponectin globular domain, FEBS Lett, 586, 912, 10.1016/j.febslet.2012.02.024 · DOI
  15. ML Narasimhan, 2005, Osmotin is a homolog of mammalian adiponectin and controls apoptosis in yeast through a homolog of mammalian adiponectin receptor, Mol Cell, 17, 171, 10.1016/j.molcel.2004.11.050 · DOI · Paper page
  16. L Ma, 2017, A potent peptide as adiponectin receptor 1 agonist to against fibrosis, J Enzyme Inhib Med Chem, 32, 624, 10.1080/14756366.2017.1284067 · DOI
  17. L Sun, 2017, Activation of Adiponectin Receptor Regulates Proprotein Convertase Subtilisin/Kexin Type 9 Expression and Inhibits Lesions in ApoE-Deficient Mice, Arterioscler Thromb Vasc Biol, 37, 1290, 10.1161/ATVBAHA.117.309630 · DOI
  18. TB R, 1997, Improvement of oral peptide bioavailability: Peptidomimetics and prodrug strategies, Adv Drug Deliv Rev, 27, 235

Cited by

See all 44

Metadata

Authors
Kim, S., Lee, Y., Kim, J. W., Son, Y.-J., Ma, M. J., Um, J.-H., Kim, N. D., Min, S. H., Kim, D. I., & Kim, B. B.
Venue
PLOS ONE
Published
2018-06-18
Volume
13
Issue
6
Pages
e0199256
ISSN
1932-6203 (ISSN-L)
OpenAlex
W2808856645
Cited by
44
References
8
FWCI
3.41
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.